• Home
  • Site Map
  • Privacy Policy
    •

    Zegerid (omeprazole/sodium bicarbonate)

    Expanding the Meaning of Acid Control

  • Acid Control
  • Provide More Options for your Patients
  • Coast-to-Coast Managed Care Coverage
  • Information for Pharmacists
  • Tips and Tools
  • Prescribing Information
  • Sign-up for More Information
  • Consumer Website
    •

    Print the ZEGERID Savings Coupon and help your patients start saving today!

    ZEGERID has a distinctive pharmacokinetic profile that provides immediate release and continued acid control.

    • ZEGERID is the Only Immediate-Release Oral PPI that provides rapid and continued acid control

    Distinctive pharmacokinetic profile compared to other oral PPIs1

    • Both capsules and powder for oral suspension are immediate-release formulations2
      • Both provide immediate release of omeprazole for rapid absorption in approximately 30 minutes1, 2
    • Built-in buffer protects omeprazole from acid degradation by raising intragastric pH1
    • There is no enteric coating on ZEGERID Capsules or Powder for Oral Suspension2

    All other oral PPIs are delayed-release3-7

    • Delayed-release PPIs - including oral suspensions, disintegrating tablets, and capsules - require enteric coatings to protect against acid degradation.3-8
    • Enteric coatings delay absorption and initial acid suppression3-8

    Next: Unique Immediate-Release Technology

    References
    1. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005;6:2501-2510.
    2. ZEGERID Prescribing Information, Santarus, Inc. January 2008.
    3. Aciphex Prescribing Information. Eisai Inc. and Janssen Pharmaceutica Inc. February 2007.
    4. Nexium Prescribing Information. AstraZeneca. April 2007.
    5. Prevacid Prescribing Information. TAP Pharmaceutical Products, Inc. July 2007.
    6. Prilosec Prescribing Information. AstraZeneca. July 2007.
    7. Protonix Prescribing Information. Wyeth Pharmaceuticals, Inc. December 2007.
    8. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release, esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms, Aliment Pharmacol Ther. 2007; 25:197-205.
    9. Wolters Kluwer Health Source™ Dynamic Claims™. Note that a portion of these approvals may have been reversed by the patient.
    ~90% of ZEGERID claims were approved for payment through April, 2008.9

    View coverage information for your patients with the ZEGERID Managed Care Map



    Please see full prescribing information.

    You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

    Product Description
    ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

    Indications and Dosing for ZEGERID
    ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
    (20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
    (20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

    Important Safety Information about ZEGERID
    The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for Oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for Oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 13 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

    ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for Oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

    Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

    Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
    1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

    © 2008 Santarus, Inc. All rights reserved. 1-ZEG08020

    Use of this site constitutes your acceptance of our Terms of Use and Privacy Policy.